Effect of eicosapentaenoic acid and docosahexaenoic acid supplementation on C-peptide preservation in pregnant women with type-1 diabetes: randomized placebo controlled clinical trial.

What Was Tested

The paper reports a study of C-Peptide, published as a randomized controlled trial.

Type-1 diabetes mellitus (T1DM) is caused by autoimmune insulitis.

There are evidences that pregnancy and n-3 fatty acids exhibit suppressive effect on human inflammatory system.

Who Took Part

The abstract describes 43 women taking part.

PubMed indexes the participants as young adults and adults, women only.

Ninety pregnant women with T1DM were included in the prospective randomized placebo controlled clinical trial.

Duration of T1DM in all participants was between 5 to 30 years.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this C-Peptide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the C-Peptide group a baseline to be compared against.

Blood samples were analyzed from all pregnant women for fasting C-peptide (FC-peptide), fasting plasma glucose (FPG) and HbA1c in each trimester throughout pregnancy and after delivery.

Umbilical vein blood was analyzed for fetal C-peptide level, glucose concentration and insulin resistance.

What Was Measured

Topics PubMed links to this paper include Biomarkers, C-Peptide, Combined Modality Therapy, Diabetes Mellitus, Type 1, Diet, Diabetic, Dietary Supplements and Docosahexaenoic Acids.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of C-Peptide in 43 women.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (European journal of clinical nutrition), a journal based in England.

More context: the C-Peptide compound page, all human trials.